This publication reviews the use of dostarlimab, an immune checkpoint inhibitor targeting the programmed cell death protein-1 receptor, for the treatment of advanced or recurrent endometrial cancer in both the first- and second-line setting. Dostarlimab (Jemperli) is licensed in New Zealand for use in combination with platinum-containing chemotherapy in adults with primary advanced or recurrent endometrial cancer, and as monotherapy for adults with recurrent or advanced mismatch repair-deficient endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
Please login below to download this issue (PDF)